CYDY Company Profile

CYDY Time & Sales

CYDY Recent News

CYDY Filings

CYDY Financials

CYDY Buy Rating

Buddyboy20

07/24/2025 10:47:19 AM

Apparently, Colorectal Cancer (CRC) (19)

PennySlayer

07/24/2025 10:34:58 AM

They also have not signed an office (1)

hoops

07/24/2025 10:11:22 AM

Sorry. Must be a glitch on Schwab. (1)

hoops

07/24/2025 9:34:26 AM

The manipulation gets ridiculous. 18K (1)

Hyperbolic

07/24/2025 9:08:36 AM

Would you care to (2)

pnwtri

07/24/2025 8:22:16 AM

Pestell is going to bring this thing (4)

HHIGambler

07/24/2025 6:05:46 AM

I sent the link to the admin and (2)

ohm20

07/24/2025 4:06:45 AM

What does this mean? That he needs a (5)

skezan

07/23/2025 11:31:55 PM

CNPV fun facts: FAQs: Commissioners (8)

HouseofCards

07/23/2025 9:39:53 PM

We can still sell like 250M shares if (2)

mfglola

07/23/2025 9:11:09 PM

So FDA is now accepting applications (8)

biloxiblues

07/23/2025 8:29:23 PM

We will be fine! (2)

sean007

07/23/2025 8:01:14 PM

Money is never out of (4)

Mr3Putt

07/23/2025 6:35:43 PM

Thoughts? Upwithstock IIRC has (5)

bucweey34

07/23/2025 6:08:28 PM

Question for those with more knowledge (1)

Buddyboy20

07/23/2025 5:50:30 PM

"I still vividly remember the sharp (8)

sean007

07/23/2025 5:43:23 PM

"Beneath the surface"...remains the (1)

KenChowder

07/23/2025 5:29:34 PM

Sherlock, companies who make tender (6)

sjacobs26

07/23/2025 4:41:02 PM

I could be off here, but considering (10)

sherlock57

07/23/2025 3:57:35 PM

Sunray--Imagine the response of the (18)

cardamine

07/23/2025 3:07:08 PM

Wiki even makes a separate section for (2)

cardamine

07/23/2025 2:53:12 PM

yeah there's been the proverbial "blood (1)

sunray3

07/23/2025 1:12:31 PM

Oh, I'm sure as I suspect you are that (7)

twinter11

07/23/2025 12:57:30 PM

"I don't pretend to know the motives (7)

sunray3

07/23/2025 12:07:51 PM

Now mind you, I don't pretend to know (3)

sunray3

07/23/2025 11:11:08 AM

Definitely BS, you're right...the MM (7)

Tprovo

07/23/2025 10:43:31 AM

Gap filled at .28 this AM and so did my (2)

Evil Rabbit

07/23/2025 10:03:41 AM

That premarket action was some BS. 11k (6)

dfwl28

07/23/2025 9:55:10 AM

Side effects of Ipilimumab, also known (4)

ohm20

07/23/2025 4:01:10 AM

Ipilimumab Safety Profile: Associated (16)

ohm20

07/23/2025 3:50:15 AM

Based on above hypothesis, It could (11)

KenChowder

07/23/2025 3:13:18 AM

MGK wrote: Based on above hypothesis, (11)

ohm20

07/23/2025 2:56:21 AM

Sorry Ohm, I'm not smart enough to (13)

USS JOHNSTON

07/22/2025 11:27:56 PM

I am also not a doctor, biloxi, so I (5)

MGK_2

07/22/2025 8:09:36 PM

I wrote (4)

biloxiblues

07/22/2025 7:37:02 PM

I am not a Doctor, but this is (4)

craigakess

07/22/2025 7:24:09 PM

Thanks for posting the response. (5)

Mr3Putt

07/22/2025 7:05:07 PM

UWS responds to you at r/Livimmune: (3)

SeeWhyDY

07/22/2025 5:49:35 PM

Am I reading this article (2)

skezan

07/22/2025 4:42:55 PM

Sorry Ohm, I'm not smart enough to (2)

ohm20

07/22/2025 3:34:27 PM

Ipilimumab is an antibody that binds to (10)

craigakess

07/22/2025 1:50:53 PM

Thanks for posting that as it is quite (6)

craigakess

07/22/2025 1:36:36 PM

Strange that it says the study was (2)

sean007

07/22/2025 1:34:19 PM

Europe Not entire (1)

Boatbuilder

07/22/2025 1:15:30 PM

Unfortunately not CYDY. (2)

docj

07/22/2025 12:28:38 PM

Good to see your post. It has been a

KenChowder

07/22/2025 11:16:35 AM

Another poster corrected me on the time (4)

Mr3Putt

07/22/2025 10:44:56 AM

The Jun 24 PR stated that the company (8)

sunray3

07/22/2025 10:36:07 AM

Well, I must admit that's a compelling (11)

Jake2212

07/22/2025 9:25:56 AM

sunray: Sounds good, but keep in mind. (10)

Newer

Older

Recent Articles

• Bioretec Ltd Adjusts H1 Report: Financial Highlights and Outlook
• Tetragon Financial Group Reveals September 2025 Insights
• Bioretec Ltd Updates Financial Report Details for 2025
• Loomis Reports Robust Performance in Q3 2025 with Growth
• Investments from Optiver and Qube Strengthen McKay Brothers
• Strategic Investments by Optiver and QRT Propel McKay Brothers
• Mycenax Partners with RIN Institute to Transform ADC Technology
• Transforming Enterprises: FastGPT's No-code AI Solutions for 2025
• Corbus Pharmaceuticals Moves Forward with Public Offering
• S&P 500 Achieves Historic Winning Streak and Market Insights
• Key Challenges Highlighted by Michael Saylor for Growth Strategy
• Ecer.com Launches Innovative AI Marketplace Strategy for Trade
• Bioretec Ltd Revises 2025 Half-Year Report with Key Updates
• DigitalXForce Achieves Prestigious Leader Status in IDC Assessment
• Danske Bank Sees Positive Trends and Growth for 2025
• Sampo plc's Latest Share Buyback Program and Results
• Exciting Developments in Kudu Well Appraisal by BW Energy
• Aalberts N.V. Strengthens Position with GVT Acquisition
• Nxera Pharma's Innovations and Financial Report for 2025
• Nxera Pharma Expands Manufacturing to Meet Growing Demand for QUVIVIQ®
• Vistin Pharma Reports Strong Q3 Results and Market Growth
• Corbus Pharmaceuticals Sets Price for New Stock Offering
• Introducing a New Executive Team Member at Realkredit Danmark
• Aalberts Enhances Market Position Through Latest Acquisition
• Exploring the Future of Green Hydrogen Development
• Aker Solutions ASA Sees Revenue Boost in Third Quarter
• Aker Solutions Reports Strong Performance in Q3 2025
• Aker Solutions’ Record Growth and Promising Future Outlook
• Investigation Launched into Conduent's Major Data Breach Event
• Vallourec Secures Groundbreaking Contract for Deepwater Project
• Essential Patient Inquiries for Portable X-Ray Scheduling
• Exploring Affordable Coastal Living Alternatives Near Beaches
• Intensity Therapeutics Sees Dip After Surging to New Heights
• Marimekko's Strategic Growth and Operations in 2025
• SCOR Reports Impressive Q3 2025 Earnings and Growth Metrics
• SPIE Reports Robust Growth and Strategic Acquisitions in 2025
• Trifork Group Achieves 4.7% Revenue Growth in Q3 Growth Report
• Ekspress Grupp’s Revenue Growth and Future Strategies Unveiled
• Marimekko Sees Growth in Q3 Revenue and Profits for 2025
• Syensqo's Strategic Shift: Selling Oil & Gas Division to SNF
• Elis Expands its Reach in Germany with New Acquisition Deal
• Biotalys' EVOCA Biofungicide Nears EPA Approval, Changing Crop Protection
• Hyundai and NVIDIA Unite for Advanced AI Innovation
• Transforming Manufacturing: NVIDIA and SK Group's AI Collaboration
• NVIDIA and Samsung Launch Revolutionary AI Manufacturing Factory
• NVIDIA and South Korea Join Forces to Revolutionize AI Landscape
• Vallourec Secures Major Offshore Contract with TechnipFMC
• SCOR Achieves Remarkable Q3 2025 with Strong Net Income
• Realsee Partners with Linkhome to Transform Real Estate with AI
• Revolutionizing Retirement: How Physicians Are Investing Wisely